for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zynerba's cannabis-based drug for rare genetic disorder fails study

June 30 (Reuters) - Zynerba Pharmaceuticals Inc said on Tuesday its experimental cannabinoid gel, Zygel, did not meet main and key secondary goals of a pivotal trial in patients with a neurological disorder called Fragile X syndrome.

Fragile X syndrome (FXS) is characterized by mild-to-moderate intellectual disability. (Reporting By Mrinalika Roy in Bengaluru; Editing by Maju Samuel)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up